Realm Therapeutics plc (RLM)

October 19, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 2.9

Price Open 2.84

Volume: 338

Avg Volume: 11,892

Market Cap: 13.52M

P/E Ratio -

52 Wk Range -13


Realm Therapeutics provides corporate update and hires advisor to support strategic review (2018-09-17 08:50 SeekingAlpha)

Realm Therapeutics ( RLM ) provides a corporate update following the August 14, announcement of top-line results of the Company's Phase 2 trial of PR022 in Atopic Dermatitis. More news on: Realm Therapeutics PLC, Healthcare stocks news, Read more …


Realm Therapeutics Provides Corporate Update and Hires Advisor to Support Strategic Review including Formal Sale Process (2018-09-17 07:00 PR Newswire)

MALVERN, Pa. , Sept. 17, 2018 /PRNewswire/ --Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a biopharmaceutical company with a proprietary technology platform of stabilized high concentration hypochlorous acid (HOCl), today provides a corporate update following the August 14, 201…



Shares Outstanding: 4.66M

Top 15 Institution Percent: N/A

Price To Sales: 26.94

Price To Book: N/A

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -79.47

Return On Equity: -87.18

Profit Margin: N/A

Price History

Beta: 0.00

50-day Moving Avg: N/A

200-day Moving Avg: N/A

YTD Change: -56.97

5-day Change: 2.83

1-month Change: -54.69

3-month Change: -56.97

6-month Change: -56.97

1-year Change: -56.97

Revenue Per Share: 0.00

Revenue Per Employee: 0.00


Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -

Company Profile

Name: Realm Therapeutics plc

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare


Realm Therapeutics PLC is a biopharmaceutical company which focuses on leveraging its proprietary immunomodulatory technology to protect and improve the health of adults and children.